Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.
Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when treated with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback